中国现代药物应用
中國現代藥物應用
중국현대약물응용
CHINESE JOURNAL OF MODERN DRUG APPLICATION
2015年
2期
3-5
,共3页
雷珠单抗%玻璃体腔注射%曲安奈德%视网膜静脉阻塞%黄斑水肿
雷珠單抗%玻璃體腔註射%麯安奈德%視網膜靜脈阻塞%黃斑水腫
뢰주단항%파리체강주사%곡안내덕%시망막정맥조새%황반수종
Ranibizumab%Intravitreal injection%Triamcinolone acetonide%Retinal vein occlusion%Macular edema
目的：评价玻璃体腔注射雷珠单抗(ranibizumab)联合筋膜囊下注射曲安奈德(TA)治疗视网膜静脉阻塞(RVO)继发黄斑水肿(ME)的临床疗效。方法经眼底荧光血管造影(FFA)及光学相干断层扫描(OCT)检查确诊为RVO合并黄斑水肿的患者30例,30眼。对比分析单次玻璃体腔注射雷珠单抗联合筋膜囊下注射TA治疗前后最佳矫正视力(BCVA)、OCT的变化。结果治疗前与治疗后1周、1、3个月BCVA分别为(0.727±0.115)、(0.591±0.062)、(0.528±0.083)、(0.494±0.082)；黄斑中心厚度(CMT)分别为(482.6±75.9)μm、(402.7±77.2)μm、(344.6±72.7)μm、(310.6±68.7)μm。治疗后1周、1、3个月BCVA显著提高, CMT显著降低,与治疗前相比差异均具有统计学意义(P<0.05)；治疗后1、3个月分别与治疗后1周相比, BCVA显著提高, CMT显著降低,差异均具有统计学意义(P<0.05)；治疗后3个月和1个月相比, BCVA提高, CMT降低,但差异无统计学意义(P>0.05)。结论玻璃体腔注射雷珠单抗联合筋膜囊下注射TA可以在短期内减轻黄斑水肿、提高BCVA,为RVO继发黄斑水肿治疗提供了新的思路,但长期效果有待进一步观察。
目的：評價玻璃體腔註射雷珠單抗(ranibizumab)聯閤觔膜囊下註射麯安奈德(TA)治療視網膜靜脈阻塞(RVO)繼髮黃斑水腫(ME)的臨床療效。方法經眼底熒光血管造影(FFA)及光學相榦斷層掃描(OCT)檢查確診為RVO閤併黃斑水腫的患者30例,30眼。對比分析單次玻璃體腔註射雷珠單抗聯閤觔膜囊下註射TA治療前後最佳矯正視力(BCVA)、OCT的變化。結果治療前與治療後1週、1、3箇月BCVA分彆為(0.727±0.115)、(0.591±0.062)、(0.528±0.083)、(0.494±0.082)；黃斑中心厚度(CMT)分彆為(482.6±75.9)μm、(402.7±77.2)μm、(344.6±72.7)μm、(310.6±68.7)μm。治療後1週、1、3箇月BCVA顯著提高, CMT顯著降低,與治療前相比差異均具有統計學意義(P<0.05)；治療後1、3箇月分彆與治療後1週相比, BCVA顯著提高, CMT顯著降低,差異均具有統計學意義(P<0.05)；治療後3箇月和1箇月相比, BCVA提高, CMT降低,但差異無統計學意義(P>0.05)。結論玻璃體腔註射雷珠單抗聯閤觔膜囊下註射TA可以在短期內減輕黃斑水腫、提高BCVA,為RVO繼髮黃斑水腫治療提供瞭新的思路,但長期效果有待進一步觀察。
목적：평개파리체강주사뢰주단항(ranibizumab)연합근막낭하주사곡안내덕(TA)치료시망막정맥조새(RVO)계발황반수종(ME)적림상료효。방법경안저형광혈관조영(FFA)급광학상간단층소묘(OCT)검사학진위RVO합병황반수종적환자30례,30안。대비분석단차파리체강주사뢰주단항연합근막낭하주사TA치료전후최가교정시력(BCVA)、OCT적변화。결과치료전여치료후1주、1、3개월BCVA분별위(0.727±0.115)、(0.591±0.062)、(0.528±0.083)、(0.494±0.082)；황반중심후도(CMT)분별위(482.6±75.9)μm、(402.7±77.2)μm、(344.6±72.7)μm、(310.6±68.7)μm。치료후1주、1、3개월BCVA현저제고, CMT현저강저,여치료전상비차이균구유통계학의의(P<0.05)；치료후1、3개월분별여치료후1주상비, BCVA현저제고, CMT현저강저,차이균구유통계학의의(P<0.05)；치료후3개월화1개월상비, BCVA제고, CMT강저,단차이무통계학의의(P>0.05)。결론파리체강주사뢰주단항연합근막낭하주사TA가이재단기내감경황반수종、제고BCVA,위RVO계발황반수종치료제공료신적사로,단장기효과유대진일보관찰。
Objective To evaluate the clinial effect of intravitreal injection of ranibizumab combined with membrane sac injection of triamcinolone acetonide (TA) in the treatment of retinal vein occlusion (RVO) complicated with macular edema (ME). Methods There were 30 patients (30 eyes) who were diagnosed as RVO with macular edema by fundus fluorescence angiography (FFA) and optical coherence tomography (OCT). The changes of best corrected visual acuity (BCVA) and OCT were compared before and after the treatment by intravitreal injection of ranibizumab combined with membrane sac injection of TA. Results The BCVA before injection and after 1 week, 1 month, and 3 months of injection were (0.727±0.115), (0.591±0.062), (0.528±0.083), and (0.494±0.082). Central macular thickness (CMT) were (482.6±75.9) μm, (402.7±77.2)μm, (344.6±72.7)μm, and (310.6±68.7)μm respectively. BCVA was remarkably increased and CMT decreased after 1 month, 3 months, and 1 week of treatment, and the difference with those before treatment had statistical significance (P<0.05). Compared with those in 1 week after treatment BCVA increased and CMT decreased in 1 month and 3 months after treatment, and the difference had statistical significance (P<0.05). The difference between 1 month and 3 month after treatment of increased BCVA and decreased CMT had no statistical significance (P>0.05). Conclusion The treatment by intravitreal injection of ranibizumab combined with membrane sac injection of TA can reduce macular edema in short time and increase BCVA. It provides a new idea for treating RVO complicated with macular edema, however, its long-term effect requires further observation.
